Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.81 |
| ▸ | PGR | P06401 | 4/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | DRD2 | P14416 | 1/20 | 0.81 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.80 |
| ▸ | USP2 | O75604 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | MLNR | O43193 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.70 |
| ▸ | PPARG | P37231 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888415 | 0.96 | NR3C1 (0.86) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL14867458 | 0.95 | NR3C1 (0.84) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL10866660 | 0.95 | NR3C1 (0.83) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL3021332 | 0.95 | NR3C1 (0.83) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL29438083 | 0.95 | NR3C1 (0.83) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL10866655 | 0.95 | NR3C1 (0.83) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL10866663 | 0.95 | NR3C1 (0.83) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL11435825 | 0.94 | NR3C1 (0.77) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL11422640 | 0.94 | NR3C1 (0.77) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL11520052 | 0.93 | NR3C1 (0.90) | NR3C1PGRNR1I2MAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660268-B2 | Emulsified gel composition | HISAMITSU PHARMACEUTICAL CO.. INC. (JP) | 2023-05-30 | — | — | US | disclosed |
| WO-2023017790-A1 | CLEANING COMPOSITION AND PRODUCTION METHOD FOR SAME | ロート製薬株式会社 | 2023-02-16 | — | — | WO | disclosed |
| CN-111787953-B | Emulsified gel composition | 久光制药株式会社 | 2022-12-09 | — | — | CN | disclosed |
| US-11246830-B2 | Emulsified gel composition | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2022-02-15 | — | — | US | disclosed |
| US-11219601-B2 | — | — | 2022-01-11 | — | — | US | disclosed |
| EP-3760231-A1 | EMULSIFIED GEL COMPOSITION | Hisamitsu Pharmaceutical Co., Inc. (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200397694-A1 | EMULSIFIED GEL COMPOSITION | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2020-12-24 | — | — | US | disclosed |
| CN-111787953-A | Emulsified gel composition | 久光制药株式会社 | 2020-10-16 | — | — | CN | disclosed |
| US-20200138695-A1 | COSMETIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-07 | — | — | US | disclosed |
| EP-3616683-A1 | COSMETIC COMPOSITION | Rohto Pharmaceutical Co., Ltd. (JP) | 2020-03-04 | — | — | EP | disclosed |
| US-20150202243-A1 | HDC Activation Inhibitor, HDC Activation Inhibition Composition, Antipruritic Agent, and Antipruritic Agent Composition | HOYU CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| CN-101754765-B | Emulsion compositions | ROHTO PHARMA | 2013-04-17 | — | — | CN | disclosed |
| CN-102008729-A | Composition for external use | ROHTO PHARMA | 2011-04-13 | — | — | CN | disclosed |
| US-20100209364-A1 | Emulsified Composition | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| CN-101754765-A | emulsion compositions | ROHTO PHARMA | 2010-06-23 | — | — | CN | disclosed |
| US-20100021405-A1 | EXTERNAL PREPARATION FOR SKIN | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| CN-101534862-A | External preparation for skin | ROHTO PHARMA (JP) | 2009-09-16 | — | — | CN | disclosed |
| US-20080207560-A1 | Composition For External Use | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| CN-101102797-A | External composition | ROHTO PHARMA (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1849481-A1 | COMPOSITION FOR EXTERNAL USE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138695-A1 | COSMETIC COMPOSITION | CUTA, LAGE3, SMURF1 | NR3C1 4161/4885PGR 951/4885NR1I2 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.